News Quantified

GNPX – genprex, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting [Yahoo! Finance]

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up [Yahoo! Finance]

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer [Yahoo! Finance]

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

-6.4%

MISS

0.9%

MISS

Form S-8 Genprex, Inc.

Form 10-K Genprex, Inc. For: Dec 31

Form 424B5 Genprex, Inc.

Form 8-K Genprex, Inc. For: Mar 19

Form 8-K Genprex, Inc. For: Mar 06

Top News Gainers

1/17 Form 424B5 Genprex, Inc. 228.6%

3/16 Form 3 Genprex, Inc. For: Mar 12 Filed by: Redman Michael Thomas 105.6%

11/19 Genprex Reports Positive Preclinical Data for the Treatment of Some of the Most Resistant Metastatic Lung Cancers 63.2%

1/23 Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market 32.1%

2/11 Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes 26.8%

1/29 Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy 24.4%

2/20 Form 8-K Genprex, Inc. For: Feb 19 22.0%

1/31 Form SC 13G Genprex, Inc. Filed by: INTRACOASTAL CAPITAL, LLC 18.3%

4/21 Form 8-K Genprex, Inc. For: Apr 15 18.2%

2/21 Genprex, Inc. Announces Closing of $17,500,000 Common Stock Offering At-The-Market and Without Warrants 14.2%

Top News Decliners

11/20 Genprex Announces $1.26 Million Registered Direct Offering -35.5%

1/23 Genprex Inc (NASDAQ: GNPX) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -34.3%

2/19 Form S-3MEF Genprex, Inc. -33.3%

11/22 Form 8-K Genprex, Inc. For: Nov 20 -15.3%

3/31 Form 3/A Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.8%

3/20 Form 3 Genprex, Inc. For: Mar 18 Filed by: Wilson William R Jr. -9.2%

1/21 Form 8-K Genprex, Inc. For: Jan 21 -8.7%

12/10 Form PRE 14A Genprex, Inc. For: Jan 27 -8.4%

10/4 Form S-3/A Genprex, Inc. -8.0%

3/3 Genprex to Present at the 2020 LD Micro Virtual Conference -7.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day